• news
    • Press releases
    • Blog
    • Media Coverage
    • Events
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • What is Knowledge Intensive EIS fund ?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Events
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • What is Knowledge Intensive EIS fund ?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h ChaiTime – London Feb 2026

o2h ChaiTime London February Edition in collaboration with J.P. Morgan uniting investors and founders shaping biotech in 2026.

About the event

​Join us for the first in-person o2h ChaiTime, hosted in collaboration with J.P. Morgan, taking place at J.P. Morgan Private Bank, London, on Thursday, 5 February 2026, from 14:00 onwards.

​Following the J.P. Morgan Healthcare Conference in the US, this session brings together a carefully curated group of investors, strategic partners, and industry leaders to discuss where biotech is heading in 2026.

​The afternoon will include a keynote on the broader biotech landscape, followed by two panel discussions. The first will look at how the sector is rebounding and where market and investor sentiment is heading. The second will focus on anti-obesity, next-generation therapies, and the next wave of GLP-1 innovation. The session will wrap up with informal networking over drinks.

​The London Edition will reflect this evolution. The format is being refined to focus on insight-led panel discussions, bringing together senior investors and experienced operators for an open, non-promotional conversation.

What’s on the agenda: –

14:00–14:15 – Arrivals and networking

14:15–14:20 – Welcome address by JPM

14:20–14:25 – Welcome address by Sunil Shah, CEO – o2h Ventures

14:25–14:45 – Keynote: Macro Perspectives on Global Biotech Capital Markets

14:45–15:15 – Panel I – Industry Rebound, Market Conditions and Investor Sentiment

15:15–15:30. Short break

15:30–16:00 – Panel II – Anti-Obesity, Next-Generation Therapies and GLP-1 Strategies

16:00–16:05 – Closing comments

16:05 onwards – Informal networking, drinks and refreshments

Panelists include:- 

Panel I:- Industry Rebound, Market Conditions and Investor Sentiment

Moderator – Sunil Shah, CEO – o2h Ventures

– Andy Richards CBE, Serial Entrepreneur

– Jenny Laird, VP – Search and Evaluation Neuroscience

– Eli Lilly – Sohaib Mir – Partner, LifeArc Ventures

– Ali Jazayeri – Operating Partner, SV Health Investors

Panel II:- Anti-Obesity, Next-Generation Therapies and GLP-1 Strategies

Moderator – Dr Tim Sparey. Executive Chair, Hawkhill Therapeutics

– Sutha Satkunarajah – Vice President of Strategy and Operations, Flagship Pioneering

– Wendy Winchester – Senior Director, External Partnerships, Nxera Pharma

– Dr Raj Singh Chandok – GP Partner and Clinical Leader

– Xavier Jacq – Chief Scientific Officer, MitoRx Therapeutics

Please note:
This is an invitation-only event and capacity is limited. Registrations will initially be placed on a waitlist. If your place is confirmed, you will receive a separate official invitation directly from J.P. Morgan, which is required for final registration and venue access.

o2h-ventures
05-02-2026
o2h-ventures
14:00 to 17:00 GMT
o2h-ventures
J.P. Morgan Private Bank, 60 Victoria Embankment, London EC4Y 0JP, UK

Register now

    First name

    Last name

    Email

    By signing up, I agree with the Terms of use & Privacy Policy

    Share with your friends

    Related events

    events category

    January 2026 Edition

    Event Image
    in-person organising
    calendar-icon 23rd January, 2026

    o2h ChaiTime Portfolio Pitch Day - Fund Launch Series - Jan 2026 Edition

    Join a curated mix of investors, founders, and ecosystem leaders to build new collaborations in a relaxed, down-to-earth setting. Be part of the first event kicking off our Growth Fund Launch Series.
    Watch now
    events category

    EISA 2025

    Event Image
    attending in-person
    calendar-icon 6th November, 2025

    Ready Steady Grow - Cambridge 2025

    We were delighted to participate in EISA’s Ready, Steady, Grow event in Cambridge, where Chris White joined the panel to share insights on supporting early-stage biotech innovation.
    Discover more
    events category

    Biotech Bikers - Aug 2025

    Event Image
    attending in-person organising
    calendar-icon 9th August, 2025

    Biotech Bikers - Cambridge Aug 2025

    Biotech Bikers brings together investors, founders, and scientists for cycling, networking, and idea exchange within the life sciences ecosystem.
    Discover more
    o2h-ventures
    o2h Ventures Limited
    Hauxton House,
    The Mill SciTech Park,
    Mill Lane, Hauxton
    Cambridge
    CB22 5HX
    07341612481
    invest@o2h.com
    about
    • about us
    • team
    • portfolio
    • funds
    insights and news
    • knowledge hub
    • press releases
    • blog
    • events
    • documents
    connect with us
    • linkedin
    • youtube
    • email
    Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
    Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
    o2h Ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors.
    © 2026 o2h ventures
    • Privacy Policy
    • Blog
    • Contact us

    Risk Information

    Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

    What are the key risks?

    1 – You could lose all the money you invest

    • If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

    2 – You are unlikely to be protected if something goes wrong

    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

    3 – You won’t get your money back quickly

    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

    • The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

    • If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

    4 – Don’t put all your eggs in one basket

    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

    5 – The value of your investment can be reduced

    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

    • These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

    If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)